Fresenius Kabi

The company traces its roots to a 1999 merger between the pharmaceutical subsidiary of Fresenius and Kabi Pharmacia, a Swedish firm renowned for anesthesia and intensive care expertise. This combination created a global entity headquartered in Bad Homburg vor der Höhe that now serves patients managing critical or chronic conditions worldwide. The organization operates with significant autonomy while remaining a major division under the Fresenius SE & Co. KGaA umbrella.

Fresenius Kabi delivers a vast array of products ranging from generic intravenous drugs to complete infusion systems and specialized clinical nutrition solutions. In the United States alone, the brand invested nearly $1 billion since 2017 to modernize production facilities, reinforcing its commitment to local manufacturing capabilities. Their portfolio includes lipid injectable emulsions for nutrition and a growing lineup of biosimilars targeting oncology and autoimmunity.

Recent years have brought both expansion and scrutiny. While the company opened a new IT hub in Barcelona in July 2026 to support global operations, it also faced regulatory challenges regarding product safety. High-profile recalls in mid-2026 affected the Ivenix large-volume infusion pumps due to mechanical vulnerabilities, alongside issues with glass particles in Actemra biosimilar batches and label mix-ups involving Morphine Sulfate Injection. [edit]